Tybourne Capital Management HK Ltd. Acquires Shares of 90,756 Hims & Hers Health, Inc. (NYSE:HIMS)

Tybourne Capital Management HK Ltd. bought a new stake in Hims & Hers Health, Inc. (NYSE:HIMS) during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 90,756 shares of the company’s stock, valued at approximately $1,672,000. Hims & Hers Health accounts for approximately 0.5% of Tybourne Capital Management HK Ltd.’s holdings, making the stock its 26th biggest position.

A number of other institutional investors have also recently made changes to their positions in HIMS. Vanguard Group Inc. raised its position in shares of Hims & Hers Health by 1.0% in the first quarter. Vanguard Group Inc. now owns 14,310,192 shares of the company’s stock valued at $221,379,000 after purchasing an additional 136,907 shares during the period. Price T Rowe Associates Inc. MD grew its stake in Hims & Hers Health by 239.7% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 168,427 shares of the company’s stock valued at $2,606,000 after buying an additional 118,848 shares in the last quarter. Strategic Wealth Partners Ltd. bought a new stake in Hims & Hers Health during the 1st quarter valued at $839,000. Virtu Financial LLC purchased a new stake in shares of Hims & Hers Health during the first quarter worth $638,000. Finally, Farallon Capital Management LLC boosted its holdings in shares of Hims & Hers Health by 3,890.5% in the first quarter. Farallon Capital Management LLC now owns 1,676,000 shares of the company’s stock worth $25,928,000 after acquiring an additional 1,634,000 shares during the period. Hedge funds and other institutional investors own 63.52% of the company’s stock.

Insider Activity at Hims & Hers Health

In related news, CFO Oluyemi Okupe sold 142,886 shares of the stock in a transaction dated Wednesday, November 13th. The stock was sold at an average price of $29.93, for a total transaction of $4,276,577.98. Following the completion of the sale, the chief financial officer now directly owns 112,186 shares in the company, valued at $3,357,726.98. This represents a 56.02 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Soleil Boughton sold 2,345 shares of Hims & Hers Health stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $14.65, for a total value of $34,354.25. Following the completion of the transaction, the insider now directly owns 159,796 shares in the company, valued at $2,341,011.40. This trade represents a 1.45 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 1,153,519 shares of company stock valued at $24,486,721. Insiders own 17.71% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on the company. Bank of America cut Hims & Hers Health from a “buy” rating to an “underperform” rating and dropped their price objective for the stock from $32.00 to $18.00 in a report on Thursday, November 14th. Canaccord Genuity Group increased their price target on shares of Hims & Hers Health from $24.00 to $28.00 and gave the stock a “buy” rating in a report on Tuesday, November 5th. Piper Sandler restated a “neutral” rating and issued a $21.00 price objective (up from $18.00) on shares of Hims & Hers Health in a research report on Tuesday, November 5th. Imperial Capital lowered shares of Hims & Hers Health from an “outperform” rating to an “in-line” rating in a report on Friday, August 9th. Finally, TD Cowen reissued a “buy” rating and issued a $28.00 price target on shares of Hims & Hers Health in a report on Wednesday, November 20th. One analyst has rated the stock with a sell rating, eight have issued a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat, Hims & Hers Health has a consensus rating of “Hold” and an average price target of $20.71.

Hims & Hers Health Trading Down 1.1 %

HIMS opened at $30.35 on Thursday. The stock has a market capitalization of $6.63 billion, a P/E ratio of 68.98 and a beta of 1.06. The stock has a 50-day moving average price of $21.14 and a 200-day moving average price of $19.57. Hims & Hers Health, Inc. has a 12-month low of $8.09 and a 12-month high of $35.02.

Hims & Hers Health (NYSE:HIMS) last issued its earnings results on Monday, November 4th. The company reported $0.32 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.06 by $0.26. The business had revenue of $401.56 million during the quarter, compared to analyst estimates of $382.20 million. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. Hims & Hers Health’s revenue for the quarter was up 77.1% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.04) earnings per share. On average, equities research analysts predict that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.